PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

Magalie Dosset¹,²,³,⁴,⁵, Thaïs Rivera Vargas¹,²,³, Anais Lagrange¹,²,³,⁴, Romain Boidot¹,²,⁵, Frédéric Végran¹,²,⁵, Aurelie Rousssey¹,²,³, Fanny Chalmin¹,²,³, Lucile Dondaine¹,²,³,⁴, Catherine Paul¹,²,³,⁴, Elodie Laurent Marie-Joseph⁵,⁶, François Martin⁵,⁶, Bernhard Ryffel⁵, Christophe Borg¹,²,⁵, Olivier Adotévi¹,²,⁵, François Ghiringhelli¹,²,⁵,“, and Lionel Apetoh¹,²,⁵,“,*

¹INSERM, U1231, Dijon, France; ²INSERM, U1098, Besançon, France; ³LabEx LipSTIC, Besançon, France; ⁴Université de Bourgogne Franche Comté, Dijon, France; ⁵Centre Georges François Leclerc, Dijon, France; ⁶University of Cape Town, RSA, CNRS, UMR7355, Orleans, France, IDM; ⁷Department of Medical Oncology, University Hospital of Besançon, France

ABSTRACT

Background: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could synergize with ICB remains unclear. The impact of chemotherapy on the PD-1/PD-L1 pathway and the resulting antitumor immune responses was assessed in two mouse models of colorectal cancer and validated in tumor samples from metastatic colorectal cancer patients that received neoadjuvant treatment. We demonstrated that 5-Fluorouracil plus Oxaliplatin (Folfox) drove complete tumor cure in mice when combined to anti-PD-1 treatment, while each monotherapy failed. This synergistic effect relies on the ability of Folfox to induce tumor infiltration by activated PD-1⁺ CD8 T cells in a T-bet dependent manner. This effect was concomitantly associated to the expression of PD-L1 on tumor cells driven by IFN-γ secreted by PD-1⁺ CD8 T cells, indicating that Folfox triggers tumor adaptive immune resistance. Finally, we observed an induction of PD-L1 expression and high CD8 T cell infiltration in the tumor microenvironment of colorectal cancer patients treated by Folfox regimen. Our study delineates a molecular pathway involved in Folfox-induced adaptive immune resistance in colorectal cancer. The results strongly support the use of immune checkpoint blockade therapy in combination with chemotherapies like Folfox.

Introduction

Colorectal cancer (CRC) is one of the most common and aggressive cancer despite decades of research advances. Although not given with a curative intent, combined chemotherapies such as 5-Fluorouracil plus Oxaliplatin (Folfox) are routinely used as first-line treatment for advanced CRC.¹,² However, the appearance of acquired pharmacological resistance to these therapies in most patients limits their antitumor effect, leading to tumor escape.

Evidence supports the importance of the immune cell infiltration in the prognosis of CRC. During the past two years several studies conducted in many cancers brought to light the tremendous clinical efficacy of immunotherapies targeting immune checkpoints such as the inhibitory molecule PD-1 (programmed cell death-1) or its ligand PD-L1.³,⁴ However in CRC the majority of patients, especially microsatellite stable (MSS) tumors, do not respond to these treatments.³,⁵ Recent literature highlights a range of factors such as the intratumoral immune contexture that is involved in the heterogeneous responses and failures of immune checkpoint blockade (ICB).⁶,⁷ Indeed, patients with high pre-existing CD8 T cell infiltrate in the tumor microenvironment (TME) are more responsive to such immunotherapies.³,⁸,⁹,¹⁰ Thus, in a clinical context, a desirable outcome would be to reinstate a suitable immunological environment to sensitize colorectal tumors to immune checkpoint inhibitors. For this, an approach is to combine them with other treatments that stimulate T cell immunity like chemotherapeutic agents.¹¹,¹² Studies in preclinical models indeed suggest that some chemotherapies can improve the anti-cancer efficacy of ICB.¹³

Some cytotoxic drugs have immunogenic properties that can promote the activation of the immune system.¹²,¹⁴,¹⁵ Indeed, 5-Fluorouracil (5-FU) was shown to selectively deplete Myeloid-derived Suppressor Cells (MDSCs) in vivo, while Oxaliplatin...
can trigger an immunogenic form of tumor cell death (ICD) through cell surface exposure of calreticulin (CRT), HMGB1 and ATP release.\textsuperscript{15,17} These processes can contribute to the induction of CD8 T cell antitumor immunity and therefore act to re-establish the cancer-immunity cycle described by Chen and Mellman.\textsuperscript{18} It also justifies the current clinical evaluation of Folfox in combination with immune checkpoint inhibitors in colorectal cancer. However, the molecular mechanisms by which chemotherapy could sensitize tumors to immunotherapy are still elusive.

Here, we report in mouse colorectal cancer models that Folfox induces complete tumor cure when combined with anti-PD1 therapy. We demonstrate that Folfox promotes in the TME the expression of both PD-1 on activated CD8 T cells and PD-L1 on tumor cells, thereby driving tumor adaptive immune resistance. Our findings thus indicate that the blockade of the PD-1/PD-L1 pathway prevents the adaptive immune resistance induced by Folfox in colorectal cancers.

**Results**

**Folfox combined with anti-PD-1 therapy induces complete colorectal tumor cure**

We tested the ability of chemotherapeutics commonly used to treat human colorectal cancer to potentiate anti-PD-1 therapy. To this end, CT26 colorectal tumor-bearing Balb/c mice were treated with cytotoxic drugs in combination or not with anti-PD1 therapy. These drugs were administrated as monotherapy (5-Fluorouracil, 5-FU; Mitomycin C, MMC; or Oxaliplatin, OX) or in combination 5-FU plus MMC (5-FU/MMC) or 5-FU plus OX (Folfox). Contrary to MMC and monotherapies, 5-FU, 5-FU/MMC and Folfox regimens permitted a faster delay of tumor growth before tumor relapse (Fig. 1A). Importantly, in combination with anti-PD1- therapy, the Folfox was the only treatment that led to complete and long-lasting cancer cure (Fig. 1A, B). Data of pooled experiments are represented in Fig. 1C.

Similar results were also observed in C57BL/6 mice bearing MC38 colon tumors (Supplementary Fig. 1A and B). In addition, we did not observe any cancer recurrence in Folfox/anti-PD-1 cured mice and those animals were still protected against a CT26 tumor rechallenge but not against the control 4T1 mammary adenocarcinoma tumor (Supplementary Fig. 1C). These data strongly suggest that Folfox administration creates a suitable TME that renders colorectal tumors sensitive to PD-1 blockade in vivo.

**Folfox induces functional PD-1\textsuperscript{+} CD8 TILs in the tumor microenvironment**

Next, we evaluated the effect of Folfox on immune cells within the tumor bed. Because 5-FU selectively eliminates immunosuppressive Myeloid-derived suppressor cells (MDSCs) in vivo,\textsuperscript{16} we first investigated whether Folfox induced MDSC depletion. We found that, like 5-FU, Folfox induced MDSC depletion in vivo and had no effect on regulatory T cells (Tregs) (Supplementary Fig. 2). Thus the ability of Folfox to deplete MDSCs is not sufficient to explain the robust tumor regression when combined with anti-PD1 therapy (Fig. 1).

By analyzing tumor-infiltrating lymphocytes (TILs), we found that chemotherapies led to variable levels of CD8 T cell infiltrate in tumors. Except for MMC, Folfox and other chemotherapies led to an increase of CD8 TILs compared to untreated control (Fig. 2A). But unlike other treatments, Folfox induced strong levels of IFNγ-producing CD8 TILs both ex vivo and in response to AH-1/H2-L\textsuperscript{d} peptide expressed by CT26 tumor cells (Fig. 2B,C and Supplementary Fig. 3).

Using RNA-sequencing, we found that CD8 TILs from Folfox-treated mice have increased expression by more than 3-fold of genes encoding inhibitory receptors such as PD-1 (Pdcd1), Tim-3 (Havcr2), CTLA-4 (Cd44), LAG3 (LAG3), TIGIT (Tigitt) and NKG2A (Klrc1) (Fig. 3A). The cell surface analysis of PD-1 and Tim-3, the two main inhibitory receptors commonly used to characterize exhausted T cells,\textsuperscript{19,20} was performed in tumor-bearing mice treated by chemotherapy. As shown in Fig. 3B, we observed that chemotherapies induced variable levels of PD-1 and Tim-3 expression on CD8 TILs compared to control. Interestingly, CD8 TILs co-expressing PD-1 and Tim-3 thought to be dysfunctional cells were particularly present in the groups of mice treated with Folfox (\~{}34%) or 5-FU (\~{}24%) as compared to OX (\~{}12%) (Fig. 3C). Of note, the expression of PD-1 and Tim-3 on CD8 T cells was restricted to the tumor site where no induction of these two receptors was found in the spleen or tumor-draining lymph nodes of the treated mice (data not shown). Similar results were found in C57BL/6 mice bearing MC38 colon tumors (Supplementary Fig. 4).

Because Folfox promotes high levels of PD-1\textsuperscript{+}Tim-3\textsuperscript{+} CD8 TILs, we asked for the functionality of these cells. To this end, we sorted CD8 TILs from Folfox-treated CT26 tumor-bearing mice according to PD-1 and Tim-3 expression and studied their respective functions. Quantitative RT-PCR indicated that PD-1\textsuperscript{+}Tim-3\textsuperscript{+} and PD-1\textsuperscript{+}Tim-3\textsuperscript{+} cells featured high expression of genes encoding immune effector factors such as IFNγ (Ifig), Granzyme B (Gzmb) or Perforin (Pf1) compared to PD-1\textsuperscript{−} and Tim-3\textsuperscript{−} negative cells (Fig. 3D). In addition, more than 85% of CD8 TILs from Folfox or control mice were CD44\textsuperscript{hi}CD62L\textsuperscript{lo}, which is consistent with an effector memory phenotype (data not shown).\textsuperscript{21}

Additionally, a kinetic analysis revealed that the frequency of PD-1\textsuperscript{+} CD8 TILs from Folfox-treated mice gradually decreased overtime along with their effector functions, suggesting that inhibitory signals drove their dysfunction (Fig. 3E and Supplementary Fig. 5A,B). Consequently, adding anti-PD1 blocking antibody to Folfox in vivo prevents this CD8 T cell dysfunction and ensured a sustained antitumor response (Fig. 3F). By contrast, anti-PD-1 therapy was not able to unleash or increase the antitumor activity of CD8 TILs from 5-FU-treated mice (Fig. 3F). These results indicate that Folfox favors the early infiltration of tumors by functional PD-1\textsuperscript{+} CD8 T cells, a parameter which seems to be required to its synergistic effect with anti-PD1 therapy in vivo.

**T-bet drives PD-1\textsuperscript{+} expression on functional tumor-infiltrating CD8 T cells elicited by Folfox**

We next searched for the molecular mechanism that controls the Folfox-induced PD-1\textsuperscript{+} CD8 TILs effector function. We focused our investigation towards two transcription factors, T-
bet and Eomes, involved in CD8 T cell effector and memory differentiation.\textsuperscript{22-24} Compared to untreated or 5-FU-treated mice, higher level of T-bet (Tbx21) mRNA was detected in CD8 TILs from Folfox treated-mice (Fig. 4A and Supplementary Fig. 6A). This induction of T-bet by Folfox was especially found in PD-1\textsuperscript{+} CD8 T cells (Supplementary Fig. 6B). In contrast, the expression of Eomes (Eomes) on CD8 T cells remained globally unaltered (Fig. 4A and Supplementary Fig. 6A).

To explore the role of T-bet, we used T-bet\textsuperscript{fl/fl} CD4-Cre mice (Tbx21 floxed mice crossed to CD4 Cre mice) and Eomes\textsuperscript{fl/fl} CD4-Cre mice (Eomes floxed mice crossed to CD4 Cre mice), which respectively conditionally lack T-bet and Eomes expression in CD4 and CD8 T cells. Following treatment with Folfox,
we found that the absence of Tbx21 led to a stronger decrease in PD-1 and Tim-3 expression as compared to Eomes-deficient mice (Fig. 4B). Accordingly, the frequency of PD-1+ and Tim-3+ CD8 T cells drastically dropped in mice lacking T-bet, while no obvious changes were detected in the absence of Eomes (Fig. 4C and D). Furthermore, we observed that the lack of Tbx21 but not Eomes in T cells also completely abrogated effector function of CD8 TILs (Fig. 4E). Accordingly, the antitumor effect of Folfox was impaired in absence of Tbx21 (Fig. 4F). This demonstrates that, following Folfox treatment, not only T-bet controls the induction of PD-1+ CD8 T cells in the TME but it also dictates the ability of Folfox to induce anticancer immunity.

**PD-L1 expression on tumor cells induced by Folfox in vivo is driven by IFNγ-producing CD8 T cells**

Next, we assessed whether Folfox can also modulate PD-L1 on tumor cells. We found that Folfox administration led to a marked increase of the expression of the Cd274 gene encoding PD-L1, and of PD-L1 protein expression (78 ± 8% in Folfox vs 31±7% in untreated control) on tumor cells both in CT26 and MC38 tumor models (Fig. 5A-D). Kinetic analysis revealed that PD-L1 expression on tumor cells peaked 8 days after treatment initiation (Fig. 5E). We examined whether other drugs can modulate PD-L1 induction. As shown in Fig. 5F, OX also promoted PD-L1 expression on tumor cells in vivo but to at lesser extent than Folfox while 5-FU and MMC did not.

Because we did not find any correlation between PD-L1 induced by drugs on tumor cells in vitro and in vivo (Supplementary Fig. 7), we assumed that PD-L1 expression could be driven through an indirect mechanism. To test this, we first assessed the levels of PD-L1 expression on tumor isolated from immunocompetent or T-cell deficient Nude mice treated or not with Folfox. We observed that PD-L1 on tumor cells was drastically reduced in immunodeficient mice, indicating that T cells play a key role in PD-L1 expression upon Folfox treatment (Fig. 6A). Interestingly, depletion of CD8, but not CD4 T cells, suppressed Folfox-induced PD-L1 expression on tumor cells, demonstrating that CD8 T cells are responsible for PD-L1 expression following Folfox (Fig. 6B). As expected, neutralization of IFNγ in vivo significantly decreased PD-L1 expression on tumor cells (Fig. 6C).

Next, we searched for a potential mechanism involved in IFNγ-dependent PD-L1 expression on tumor cells. ERK, mTOR and STAT signaling have been previously reported to modulate PD-L1 expression in cancer cells. Upon treatment of CT26 cells in vitro with IFNγ, we found enhanced phosphorylation of STAT1 but not of ERK and mTOR (Fig. 6D). Furthermore, we found an upregulation of IRF1 expression which was reported to be regulated by STAT1 but not of ERK and mTOR (Fig. 6D). Additionally, IFNγ treatment induced the binding of IRF1 to the promoter of PD-L1 gene (Cd274) (Fig. 6E). Silencing IRF1 using siRNA confirmed that IRF1 was required for PD-L1 expression in response to IFNγ in CT26 cancer cells (Fig. 6F).

Taken together, these results clearly indicate that in our model IFNγ-secreting CD8 TILs are the main contributor to PD-L1 induction on tumor cells following Folfox administration.

**Immunogenic tumor cell death induced by Folfox promotes high levels of PD-L1 on tumor cells**

Because ICD induced by chemotherapies can stimulate CD8 T cells, we hypothesized that Folfox-driven PD-L1 expression may be related to ICD. We first evaluated the ability of Folfox and other chemotherapies to induce ICD in vitro in the CT26 model. By monitoring cell surface calreticulin (CRT) expression and HMGBl release, we observed that Folfox highly induced these two ICD hallmarks as compared to other drugs (Fig. 7A and B). Interestingly, a strong positive correlation was found between CRT exposure on CT26 tumor cells in vitro and PD-L1 induction on tumor cells in vivo by chemotherapies (p <
Figure 3. Folfox favors the infiltration of tumors by functional PD-1<sup>+</sup> CD8 T cells. (A) CT26 tumor-bearing mice were treated with glucose 5% (control) or Folfox. FACS-sorted CD8 TILs were pooled (n = 10/group) and subjected to RNA-sequencing. Naive CD8 T cells were used as reference. Heatmap of expression of genes associated with inhibitory receptors is shown (two samples per condition). (B-C) CT26 tumor-bearing Balb/c mice (n = 6/group) were treated with the different chemotherapies. (B) Frequency of PD-1 and Tim-3 was determined by flow cytometry (Kruskal-Wallis test). (C) Representative dot plot of PD-1 and Tim-3 expression on CD8 TILs. (D) Percoll-isolated TILs were harvested from Folfox-treated mice. (Left) CD8 TILs (n = 4) were FACS-sorted according to PD-1 and Tim-3 expression. mRNA IFNγ (ifng), Perforin (prf1) and Granzyme B (gzmB) expression was measured in each subset by RT-PCR. β-Actin was used as reference (Mean ± s.d of experimental replicates, Kruskal-Wallis test). (Right) Frequency of IFNγ, TNF-α, and CD107a produced by CD8 TILs after anti-CD3 stimulation (Mean ± s.d, Kruskal-Wallis test). (E) CD8 TILs were FACS-sorted according to PD-1 and Tim-3 expression. Relative mRNA expression to actin of IFNγ (ifng), Perforin (prf1), Granzyme B (gzmB) and TNF-a (tnfa) by RT-PCR at day 8 and day 17 post-treatment (Mean ± s.d of experimental replicates, Mann-Whitney test). (F) CT26 tumor-bearing Balb/c mice (n = 3-4/group) were treated with glucose 5% (control) or Folfox combined or not with anti-PD1 therapy. IFNγ and CD107a produced by CD8 TIL 12 and 20 days after treatment (Mean ± s.d., Sidak test). *p < 0.01; ns, not significant. Data are representative of one (A), two (E,F) or at least three (B-D) independent experiments. See also Supplementary Figs. 4 and 5.
Comparable results were obtained with MC38 colorectal cancer as well as with LLC1 mouse lung cancer models treated with Doxorubicin (Doxo), an ICD inducer, suggesting that this effect could be extended to other tumor types (Supplementary Fig. 8).

To confirm that ICD accounts for PD-L1 induction in vivo, we monitored PD-L1 expression on tumor cells in Toll-like receptor 4 (TLR4) deficient mice that cannot mount an immune response following ICD induction. TLR4 is indeed one of the receptors of HMGB1 and reported to be required to tumor control upon ICD induction. In the absence of TLR4, the induction of PD-L1 expression on tumor cells by Folfox is abrogated (Fig. 7D), indicating that ICD is required for PD-L1 expression on tumor cells in vivo.
Folox neoadjuvant chemotherapy stimulates ICD along with increased CD8 infiltrate and PD-L1 expression in the tumors of metastatic colorectal cancer patients

We eventually addressed the effect of Folfox chemotherapy on the TME in humans. To this end, we analyzed 9 tumor tissue samples from patients with stage IV colorectal cancer before and after 6 cycles of neoadjuvant Folfox regimen before surgery. The patients’ main disease characteristics are depicted in Table 1. Our results revealed that PD-L1 expression was significantly higher in tissue samples after Folfox and this upregulation was noted in 5 out of 9 (56%) of patients (Fig. 8).

Interestingly, Folfox chemotherapy was associated with an increase of CD8 TILs as well as with higher expression of LC3B puncta, a marker of autophagy and also reported as a surrogate marker of ICD induction in humans (Fig. 8). Taken together, these results support the links between Folfox-induced ICD, CD8 T cell infiltration and PD-L1 expression in human colorectal cancers.

Discussion

In this study, we investigated the rationale to combine chemotherapy with anti-PD1 therapy in colorectal cancer. By using two mouse colorectal cancer models, we found that Folfox plus anti-PD-1 treatment induced complete and long-lasting tumor cures in mice.

We found that Folfox induced strong expression of immune checkpoints such as PD-1 on activated CD8 TILs. In return, the IFNγ secreted by Folfox-induced CD8 T cells drove PD-L1 expression on tumor cells. Similar effect of Folfox was observed in colorectal cancer patients. Indeed, an increased CD8 cell infiltrate and tumor PD-L1 expression were found in metastatic colorectal cancer patients after Folfox neoadjuvant therapy.
These observations are in line with the concept of adaptive immune resistance that has been defined as a dominant mechanism of tumor escape in the tumor microenvironment. Thus, the upregulation of PD-L1 by tumor cells in response to IFNγ secreted by CD8 T cells is an adaptive immune resistance mechanism to Folfox. This finding could also represent an escape mechanism to Folfox therapy in colorectal cancer.

In mouse and human melanoma, the success of immune checkpoint blockade relies on the inhibition of adaptive immune resistance. Thus, the upregulation of PD-L1 by tumor cells in response to IFNγ secreted by CD8 T cells is an adaptive immune resistance mechanism to Folfox. This finding could also represent an escape mechanism to Folfox therapy in colorectal cancer.

Figure 6. PD-L1 tumor expression upon Folfox chemotherapy is driven by IFNγ produced by CD8 T cells. (A) CT26 tumor-bearing immunocompetent Balb/c or immunodeficient Nude Balb/c mice were treated with glucose 5% (control) or Folfox (n = 4/group). Expression of PD-L1 determined by flow cytometry on viable tumor cells 8 days after treatment (Kruskal-Wallis test). (B-C) CT26 tumor-bearing mice (n = 5-6/group) were treated with Folfox with or without (B) anti-CD4 or anti-CD8 depleting antibodies or (C) anti-IFNγ antibody. PD-L1 expression on tumor cells 8 days after treatment (Kruskal-Wallis test). (D-F) CT26 tumor cells were cultured with or without recombinant mouse IFNγ (10 ng/mL). (D) Kinetic analysis of indicated proteins by Western Blot. β-actin was used as control. (E) ChIP analysis of the binding of IRF1 to the putative binding site −344 of the Cd274 (PD-L1) promoter. (F) CT26 tumor cells were transfected with siRNA IRF1 or siRNA control then cultured with or without IFNγ for 24 H. Relative expression level of Ifr1 and Cd274 to untreated siRNA control-transfected cells is shown. β-Actin was used as the internal control and data were normalized to untreated siRNA control (Mean ± s.d. of technical replicates, one-way anova test). "p < 0.01; ns, not significant. Data are representative of two independent experiments.

These observations are in line with the concept of adaptive immune resistance that has been defined as a dominant mechanism of tumor escape in the tumor microenvironment. Thus, the upregulation of PD-L1 by tumor cells in response to IFNγ secreted by CD8 T cells is an adaptive immune resistance mechanism to Folfox. This finding could also represent an escape mechanism to Folfox therapy in colorectal cancer.

In mouse and human melanoma, the success of immune checkpoint blockade relies on the inhibition of adaptive immune resistance. Thus, the upregulation of PD-L1 by tumor cells in response to IFNγ secreted by CD8 T cells is an adaptive immune resistance mechanism to Folfox. This finding could also represent an escape mechanism to Folfox therapy in colorectal cancer.

Could also explain the lack of efficacy of anti-PD-1 when combined to other drugs such as 5-FU or MMC, which do not stimulate functional PD-1⁺ CD8 TILs in vivo. Of note, we observed in our mouse model that the Folfox-induced PD-1⁺ CD8 TILs decrease together with their antitumor function after two weeks, suggesting that the administration of immune checkpoint inhibitors should be given concomitantly or early after Folfox therapy.

We further deciphered the mechanism by which Folfox induced adaptive immune resistance. PD-1 induction on CD8 TILs was dependent on T-bet, while PD-L1 on tumor cells required IFNγ/IRF1 signaling. This T-bet-dependent PD-1 expression is in discrepancy with studies conducted in mouse models of chronic viral infection reporting that T-bet repressed PD-1 expression on CD8 T cells. It has however been described that T-bet was expressed by early activated CD8 T cells. In our study, T-bet expression was assessed early after treatment, possibly explaining why we found a co-expression of T-bet and PD-1 in Folfox-induced CD8 TILs.

It has been reported that combining MDSC-targeted therapy with immune checkpoint blockade induced a robust synergistic
antitumor effect through an increased infiltration. Among the tested cytotoxic drugs, 5-FU was shown to deplete MDSC and we observed that Folfox has similar effect. In contrast to Folfox, the combination of 5-FU to anti-PD-1 does not lead to tumor cure, suggesting that the depletion of MDSC is not sufficient in this context to allow full CD8 T cell activation.

Chemotherapies inducing immunogenic tumor cell death (ICD) were reported to synergize with immunotherapy in a CD8 T cell-dependent manner. We further here demonstrate that ICD was involved in the tumor adaptive immune resistance triggered by Folfox in vivo. Indeed, Folfox generated high expression of calreticulin and HMGB1. In addition, PD-L1 induction by Folfox was decreased in TLR4-deficient mice that cannot mount a suitable immune response following ICD. Furthermore, in colorectal cancer patients treated by Folfox, LC3B (a surrogate marker of ICD) is induced along with high CD8 infiltration and PD-L1 expression in tumor. Thus combining LC3B, CD8 and PD-L1 in TME could represent a predictive biomarker to anti-PD-1 therapy efficacy in colorectal cancer patients.

In conclusion, we described for the first time PD-1/PD-L1 pathway as part of an adaptive immune resistance cycle induced by Folfox chemotherapy. The blockade of the PD-1/PD-L1 pathway prevents the emergence of such resistance mechanism to the treatment in vivo. Our study thus provides a robust rationale to use therapies like Folfox in combination with immune checkpoint inhibitors in cancer patients.

**Materials and methods**

**Experimental models and subject details**

For in vivo animal studies, animals were used between 6 and 8 weeks of age. Female BALB/cAnNj and C57BL/6Nj mice were purchased from Centre d’élèvement Janvier (Le Genest St Isle, France). TLR4-KO mice were kindly provided by Dr. Ryffel. Floxed Tbx21 and Eomes mice as well as CD4-Cre were purchased from JAX. All animal experiments were performed under protocols approved by the local ethical committee and were carried out according to the good laboratory practices defined by
the animal experimentation Rules in France. For human studies, tumor samples were collected at the Centre Georges François Leclerc (Dijon, France) and all patients had given their written consent. Tumor tissue samples from biopsies were collected from 9 stage IV metastatic colorectal cancer patients at the baseline and after 6 cycles of Folfox neoadjuvant chemotherapy before surgery. For mouse tumor cell lines, CT26 (which exhibits a microsatellite stable profile) and MC38 colon carcinoma cells, and LLC1 lung carcinoma cells were cultured in complete medium: RPMI 1640 with glutamax-1 (Lonza) supplemented with 10% Fetal Calf Serum (Lonza), 1% Penicillin, Streptomycin, Amphotericin B (Gibco). All cells were routinely tested for mycoplasma contamination using Mycoalert Mycoplasma Detection Kit (Lonza) and found negative.

**Tumor challenge and treatment**

1. $10^6$ CT26 or MC38 tumor cells were injected s.c. into the right flank of mice. When tumors reached 50–70 mm², (between day 8–10), groups were formed. Mice whose tumors did not meet

---

**Figure 8.** Impact of Folfox neoadjuvant chemotherapy in metastatic colorectal cancer patients. Tumor samples from 9 metastatic colorectal cancer patients were harvested before and after Folfox neoadjuvant chemotherapy. (A) Representative images of patients’ tumor biopsies showing PD-L1, LC3B and CD8 labeling by immunohistochemistry. L: liver, I: infiltrate, T: tumor. (B) Individual representation of patients for each parameter. Scores of 2+ and 3+ are classified as high expression. (C) Heatmap of patients before and after Folfox chemotherapy.
Table 1. Characteristics of patients with colorectal cancer (N = 9).

| Characteristics              | No. of patients |
|------------------------------|----------------|
| Age mean, years              | 62 ± 15        |
| Gender                       |                |
| Male                         | 6              |
| Female                       | 3              |
| Primary tumour               |                |
| Colon                        | 8              |
| Rectum                       | 1              |
| RAS mutation                 |                |
| Yes                          | 3              |
| No                           | 6              |
| Braf Mutation                |                |
| Yes                          | 0              |
| No                           | 9              |
| Liver metastasis             |                |
| > 3                          | 4              |
| < 3                          | 5              |
| Synchronous                  | 2              |
| Metachronous                 | 7              |

The characteristics were as follows: All chemotherapies were obtained from the Centre George François Leclerc, except for mitomycin C (MMC) (Sigma). 5-FU, OX, MMC and Irinotecan were administered i.p. once at 50 mg/kg, 6 mg/kg, 2 mg/kg and 20 mg/kg respectively. Doxorubicin (Doxo) was given once i.t. at 120 μg per mouse. Gemcitabine (Gem) was given once i.p. at 75 mg/kg. Mice from control groups were injected with the solvent used to dissolve the drugs. Anti-mouse PD-1 antibody (RMP1-14; BioXcell) injections were initiated concomitantly with the chemotherapy treatment, then given i.p. at 200 μg per mouse twice a week until the tumor reached >250 mm² or, when appropriate, until complete tumor regression. Mice whose tumors exceeded 250 mm²; were euthanized due to ethical reasons and survival curves were plotted. For rechallenge experiments, tumor-free mice were injected with 2.10⁵ CT26 on the left flank and 2.10⁴ 4T1 on the right flank. For CD8, CD4 and IFNγ depletion, anti-mouse CD8 (YTS 169.4; BioXcell), CD4 (GK1.5; BioXcell) or IFNγ antibodies (XMG1.2; BioXcell) were used. Anti-CD8 antibody was administered i.p. once at 500 μg per mouse, anti-CD4 twice every two days at 300 μg per mouse and anti-IFNγ twice a week at 300 μg per mouse.

**ELISpot IFNγ assay**

Freshly percoll-purified tumor-infiltrating lymphocytes were incubated at 5.10⁶ cells per well in duplicate in ELispot IFNγ plates (Diaclone) and in the presence of medium or AH-1/H2-Ld peptide (10 μg/mL, Proimmune) derived from gp70 antigen expressed by CT26 tumor cells. Plates were incubated for 18 h at 37°C and spots were revealed following the manufacturer’s instructions (GenProbe). Spot-forming cells were counted using the “C.T.L. Immunospot” system (Cellular Technology Ltd.).

**Western blotting**

Cells were plated at a density of 1 × 10⁵ cells onto 24-well plate. After 24 h cells were grown in X-Vivo 15 medium (Lonza) during 4 h and treated with mouse IFNγ (Miltenyi, #130-105-790) at working concentration of 10 ng/ml, diluted in X-Vivo 15 medium. 24 hours after the treatment, whole cell extracts were prepared in boiling buffer (1% SDS, 1 mM sodium orthovanadate and 10 mMTris, pH 7.4) in the presence of complete protease inhibitors (Roche Diagnostics). The viscosity of samples was diminished by sonication. Protein concentrations were measured with a Bio-Rad DC protein assay kit. Protein lysates were incubated in loading buffer (125 mMTris-HCl, pH 6.8, 10% β-mercaptoethanol, 4.6% SDS, 20% glycerol and 0.003% bromophenol blue) and heated at 95°C for 5 min, then separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, 12%) and were transferred by electroblot to nitrocellulose membrane before analysis with a chemiluminescence detection kit (ThermoFisher). The primary antibodies used for immunoblotting directed against IRF1 were from Santa Cruz Biotechnologies. p-STAT1, STAT1, p-ERK, ERK, p-mTOR, mTOR were used. The targeted bands were visualized by enhanced chemiluminescence. 

**ChIP assay**

ChIP assays were performed with a ChIP-IT express kit (Active Motif Europe) according to the manufacturer’s instructions. After enzymatic digestion, DNA was immunoprecipitated overnight at 4°C with 3 μg of anti-mouse IRF1 (H-205, Santa Cruz, sc-13041) or 2 μg of negative control immunoglobulin. After the addition of protein G beads, the mixture of protein G, antibody and chromatin was washed and eluted from the protein G with supplied buffers. Then, cross-linking was reversed and samples were analyzed by quantitative PCR. Oligonucleotide sequences are: promoter PDL1: forward 5’-GGTTCCACTCCCACCCAAA-3’; reverse 5’-AACCGGCTGCTACTGAGAG-3’. 

**siRNA transfection**

Cells were plated at a density of 1 × 10⁵ cells onto 24-well plate. After 24 h, the cells were transfected with IRF-1 siRNA (siRNA ID s7501) or control siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s recommendations. One day after the transfection, cells were grown in X-Vivo 15 medium (Lonza) during 4 h and treated with mouse IFNγ (Miltenyi) at working concentration of 10 ng/ml, diluted in X-Vivo 15 medium. 24 hours after the treatment, total RNA was isolated using Trizol reagent (Invitrogen), according to the manufacturer’s protocol. cDNA was generated using M-MLV Reverse Transcriptase (Invitrogen), which was amplified by
real-time quantitative PCR (RT-qPCR) with the SYBR Green method using the 7500 Fast Real Time PCR system (Applied Biosystems). Expression was normalized to the expression of mouse Actb. Primers designed to assess the expression of IRF1 are, forward 5'-AGGGATCCCTTTGATGATGCC-3' and reverse 5'-AAATCCACACCAATCCCCAGG-3', and of PD-L1 are, forward 5'-CTCGGCTGCAGATAGTTCC-3' and reverse 5'-GTCCAGCTCCTGGTTCTACAG-3'.

Transcriptome analyses

Tumor-infiltrating CD8 T cells from CT26-tumor bearing mice treated with Glucose 5% (control) or Folfox when tumors reached 50–70 mm² were sorted by flow cytometry 8 days following treatment. CD8 TILs cells coming from 2 independent experiments with 8–10 pooled tumors for each experiment were used. Splenic CD8 T cells from 2 naïve mice were used as reference. Total mRNA was isolated using Trizol (Gibco Life Technologies) according to the manufacturer instructions. rRNA from total RNA extracted were removed with NEBNextrRNA depletion kit (New England BioLabs). 100 ng of RNA depleted of rRNA was used for the library preparation with a NEBNext Ultra RNA library kit for Illumina according to the manufacturer’s instructions. (New England BioLabs). RNA sequencing was performed on a NextSeq 500 device (Illumina). The libraries were sequenced with paired-end 75–base pair ‘reads’. FASTQ files were mapped with the BWA software package (mm10 National Center for Biotechnology Information assembly of the Mus musculus genome) for Illumina. Analysis was performed with the splice junction mapper TopHat for Illumina. The files generated were processed with Cufflinks software to obtain annotated expressed genes in each studied subtype. Heatmaps of selected genes were generated using R software (http://www.R-project.org).

Detection of immunogenic tumor cell death induction

For fluorescence detection of cell surface CRT, tumor cells were applied on a microscope slide plated onto 12-well plate. Cells were grown 24 H in complete medium (RPMI 10% Fetal Bovine Serum 1% Penicillin-Amphotericin B), then treated for 6 H with or without 5-FU (10 μM), Oxaliplatin (OX, 50 μM), Mitomycin C (MMC, 20 μM) or 5-FU/OX (Folfox, 10 μM/50 μM). Cells were fixed at room temperature with 0.25% paraformaldehyde (PFA) for 5 min then incubated for 30 min at 4°C in PBS 3% BSA, then incubated 30 min at 4°C with primary rabbit anti-mouse anti-CRT (1:200, Abcam, ab2907) in PBS 3% BSA. The secondary antibody Alexa488-labeled donkey anti-rabbit IgG H&L (1:500, Abcam, ab150073) added in PBS 3% BSA for 30 min at 4°C. Cells were then fixed in PFA 4% for 20 min at 4°C. To measure HMGB1 release, cells were incubated for 24 H in presence of the different chemotherapies as described above. HMGB1 levels were measured by ELISA (Chondrex) according the manufacturer’s instructions.

Real-time quantitative reverse transcription PCR (RT-qPCR)

Total RNA from cells was extracted with TrizReagent (Ambion), reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen) and was analyzed by real-time quantitative PCR (RT-qPCR) with the Sybr Green method according to the manufacturer’s instructions using the ViiA™ 7 Real-Time PCR System (Applied Biosystems). The following primers were used: mouse Actb (forward: ATGGAGGGGAAATACAGCC/ reverse: TTCTTGGAGCTCCTCGT), mouse Pdcd1 (forward: GGCCTCTAGAGGTCCTACAT/ reverse: GAAGGC GGCTGTTTTTCCAG), mouse Havcr2 (forward: ATCCTTAATGGTATCCTG/ reverse: TCCTCACCCTCTATAAGTTCATG), mouse Tbx21 (forward: CCACCACGACCCATGTAAG/ reverse: CCACACGTCTTCTGCTAC), mouse Tnfa (forward: AGGGTCTGGGCCATAGAACT/ reverse: ACGCAAGGGGCAAAAGGAT), mouse Ifng (forward: TGAATCTGTGGGCCTACAGA/ reverse: ACACCAAGGCGACCAAGAGAT), mouse Tnfa (forward: AGGCTCTAGAGGTCCTACAT/ reverse: TCCTCACCCTCTATAAGTTCATG), mouse Tbx21 (forward: CCACCACGACCCATGTAAG/ reverse: CCACACGTCTTCTGCTAC), mouse Tnfa (forward: AGGGTCTGGGCCATAGAACT/ reverse: ACACCAAGGCGACCAAGAGAT), mouse Ifng (forward: TGAATCTGTGGGCCTACAGA/ reverse: ACACCAAGGCGACCAAGAGAT).

Immunohistochemistry on patients’ tumor samples

Formalin fixed, paraffin-embedded colorectal cancer biopsy tissue collected from 9 stage IV metastatic colorectal cancer patients treated or not with neoadjuvant Folfox chemotherapy were cut into 4-μm sections, mounted on slides, deparaffinized with xylene and dehydrated using a graded ethanol series. The slides were incubated overnight at 4°C using antibodies against PD-L1 (SP142; Ventana), LC3B (5F10, Nanotools) or CD8 (C8/144B, Dako). A qualitative approach was used for evaluating the expression of PD-L1, LC3B and CD8 (graded: 0 = negative, 1 = very weak, 2 = moderate, 3 = strong). A PD-L1 or LC3B score of 1–3 was evaluated as “positive”.

Statistical analysis

Statistical analysis was performed using Prism software (GraphPad software, La Jolla, CA, USA). For two-group comparisons, the Student t-test and the Mann-Whitney test were used. For multiple group comparison, the one-way or two-way ANOVA test or the Kruskal-Wallis test was used. All differences were considered statistically significant at the level of p < 0.05 ("p < 0.05, **p < 0.01). Mouse survival was estimated from the tumor size of 250 mm² by Kaplan-Meyer method and the log-rank test was corrected for multiple comparisons using the Bonferroni method, P values less than 0.01 were considered significant ("p < 0.01, **p < 0.001).
References

1. Colucci G, Gobbia V, Paolotti G, Giuliani F, Caruso M, Gobbia N, Carteni G, Agostara B, Pezzella G, Manzone L, et al. Phase II randomized trial of FOLFIIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:4866–75. doi:10.1200/JCO.2005.07.113

2. Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Lloca C, Busquier I, Campos JM, Perez-Enguita D, Balcells M. FOLFOX alternated with FOLFIIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5:263–7. doi:10.3816/CCC.2005.n.037. PMID:16356303

3. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87. doi:10.1038/nrc.2016.36. PMID:27079802

4. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–14. doi:10.1016/j.cell.2015.03.030. PMID:25860605

5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvalj DA, Rossmann A, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi:10.1056/NEJMoa1200690. PMID:22658127

6. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, McDonald DM, Andre E, Alonso AA, Dowlati A, et al. PD-L1 expression and clinical benefit in patients with tumors that harbor IDH1 or IDH2 mutations. Science. 2015;348:1240–4. doi:10.1126/science.aab0662. PMID:25964783

7. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzone L, et al. Phase II randomized trial of FOLFIIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:4866–75. doi:10.1200/JCO.2005.07.113

8. Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Lloca C, Busquier I, Campos JM, Perez-Enguita D, Balcells M. FOLFOX alternated with FOLFIIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5:263–7. doi:10.3816/CCC.2005.n.037. PMID:16356303

9. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87. doi:10.1038/nrc.2016.36. PMID:27079802

10. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–14. doi:10.1016/j.cell.2015.03.030. PMID:25860605

11. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvalj DA, Rossmann A, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi:10.1056/NEJMoa1200690. PMID:22658127

12. Galluzzi L, Buquier I, Busquier C, Cenizo J, Manca C, et al. Distinct immune and metabolic phenotypes of cancer cells determined by the tumor microenvironment. Cancer Res. 2016;70:3052–61. doi:10.1158/0008-5472.CAN-09-3690. PMID:20388795

13. Shen Z, Wallis J, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, McDonald DM, Andre E, Alonso AA, Dowlati A, et al. PD-L1 expression and clinical benefit in patients with tumors that harbor IDH1 or IDH2 mutations. Science. 2015;348:1240–4. doi:10.1126/science.aab0662. PMID:25964783

14. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Inflammation, immunity and cancer: the role of tumor-educated myeloid cells. Nature. 2011;474:448–55. doi:10.1038/nature10101. PMID:21533780

15. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzone L, et al. Phase II randomized trial of FOLFIIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:4866–75. doi:10.1200/JCO.2005.07.113

16. Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Lloca C, Busquier I, Campos JM, Perez-Enguita D, Balcells M. FOLFOX alternated with FOLFIIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5:263–7. doi:10.3816/CCC.2005.n.037. PMID:16356303

17. Shen Z, Wallis J, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, McDonald DM, Andre E, Alonso AA, Dowlati A, et al. PD-L1 expression and clinical benefit in patients with tumors that harbor IDH1 or IDH2 mutations. Science. 2015;348:1240–4. doi:10.1126/science.aab0662. PMID:25964783
anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573–7. doi:10.1126/science.1208347. PMID: 22174255

34. Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy. 2015;11:1878–90. doi:10.1080/15548627.2015.1082022. PMID:26506894

35. Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 2014;15:190. doi:10.1186/1471-2164-15-190. PMID:24621249